Attachment prepared. The initial visit finished on 25 January with the conclusion of the Facility Attachment.

On-site inspection: one day, 26 January 1989.

9. The protection of confidential information has been secured by the mandate of the inspectors and by the Facility Attachment. After carrying out the NTI, the inspection team reached the conclusion that from Czechoslovakia's point of view the items 2.2.(a) and 2.2.(b) could be combined into one category. Another category could be the data relating to:

- the capacity of plants;
- input and output data on inspected materials;
- customers and suppliers.

The following data could be categorized as classified:

- the layout plan of plants;
- technological process and flow charts;
- specification of raw materials and products needed for compiling and evaluating the list of chemicals related to the Convention;
- the parameters of processes and the status of chemicals at sites of their balancing and measuring needed for the verification of the amount of the chemicals in accordance with the Convention.

10. The head of the inspection team submitted information on the purpose, aims and methods of carrying out the inspection and a representative of the plant reported on the readiness of the plant for the inspection.

11. The operational record for 1988 and the production plan for 1989 have been verified from written documentation.

12. An inspection has been undertaken of the production unit and the related peripherals. The operated equipment does not permit a change-over to the manufacturing of Schedules [1] and [2] chemicals without major engineering and construction alterations.

13. The sites and facilities have been determined which were subject to inspection.

14. A comparison has been made between the operated technological process and the process flow sheet on-site. It has been established that the quantity of the input raw materials was in conformity with the end products and the quantity of the processed substances under observation was in conformity with the indicated production of Spolapret OS.

15. Samples were taken as needed in predetermined locations, they were sealed and conveyed to an authorized testing facility under the supervision of an